Paradigm Biopharmaceuticals (Paradigm Biopharmaceuticals) Sloan Ratio % : 0.00% (As of Dec. 2023)

Paradigm Biopharmaceuticals Sloan Ratio % Chart

Paradigm Biopharmaceuticals Semi-Annual Data
	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Sloan Ratio %	Get a 7-Day Free Trial												-	-	-	-	-

Competitive Comparison of Paradigm Biopharmaceuticals's Sloan Ratio %

For the Biotechnology subindustry, Paradigm Biopharmaceuticals's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Paradigm Biopharmaceuticals's Sloan Ratio % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Paradigm Biopharmaceuticals's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where Paradigm Biopharmaceuticals's Sloan Ratio % falls into.

Paradigm Biopharmaceuticals Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

Paradigm Biopharmaceuticals's Sloan Ratio for the fiscal year that ended in Jun. 2023 is calculated as

Paradigm Biopharmaceuticals's Sloan Ratio for the quarter that ended in Dec. 2023 is calculated as

For company reported semi-annually, GuruFocus uses latest two semi-annual data as the TTM data. Paradigm Biopharmaceuticals's Net Income for the trailing twelve months (TTM) ended in Dec. 2023 was -13.452 (Jun. 2023 ) + -32.77 (Dec. 2023 ) = $-46.22 Mil.
Paradigm Biopharmaceuticals's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2023 was -18.411 (Jun. 2023 ) + -34.152 (Dec. 2023 ) = $-52.56 Mil.
Paradigm Biopharmaceuticals's Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2023 was 0 (Jun. 2023 ) + 0.031 (Dec. 2023 ) = $0.03 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Paradigm Biopharmaceuticals  (OTCPK:PBIGF) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Dec. 2023, Paradigm Biopharmaceuticals has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.

Paradigm Biopharmaceuticals Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of Paradigm Biopharmaceuticals's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.

Paradigm Biopharmaceuticals (Paradigm Biopharmaceuticals) Business Description